DSGN

Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.

Wall Street analysts forecast DSGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DSGN is 13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Design Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Design Therapeutics Inc. EPS for the last quarter amounts to -0.30 USD, increased 30.43 % YoY.

Design Therapeutics Inc (DSGN) has 54 emplpoyees as of January 10 2026.

Today DSGN has the market capitalization of 534.89M USD.